STIMPOD NMS460 Nerve Stimulator
Device Facts
| Record ID | K161091 |
|---|---|
| Device Name | STIMPOD NMS460 Nerve Stimulator |
| Applicant | Xavant Technology (Pty), Ltd. |
| Product Code | GZJ · Neurology |
| Decision Date | Jan 18, 2017 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 882.5890 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The STIMPOD NMS460 Nerve Stimulator is a Transcutaneous Electrical Nerve Stimulation (TENS) device used for symptomatic relief and management of chronic intractable pain and/or as an adjunctive treatment of post-surgical pain, post traumatic acute pain problems, as well as an adjunct for pain control due to rehabilitation.
Device Story
Handheld, low-frequency TENS device; delivers electrical pulses through skin to manage pain. Operates as current source; provides two waveforms: Monophasic Square Wave and proprietary Hybrid RF waveform (Monophasic Square Wave with superimposed Radio Frequency). Used in clinical environments by healthcare professionals. Device features automatic overload and no-load detection; automatic shut-off; user override control. Output parameters (amplitude, pulse width, frequency) are controlled by the user. Benefits include pain relief and management for chronic, post-surgical, or post-traumatic conditions. Device is powered by 4 AAA alkaline batteries.
Clinical Evidence
Bench testing only. Compliance with IEC 60601-1 (general safety), IEC 60601-1-2 (EMC), and IEC 60601-2-10 (nerve/muscle stimulator safety) confirmed. No clinical data provided.
Technological Characteristics
Handheld TENS device; ABS plastic enclosure; 316L stainless steel probe. Current source; 1 output channel. Waveforms: Monophasic Square, Hybrid RF (160kHz fixed). Max output: 43.7mA, 220V. Pulse widths: 0.1ms, 0.2ms. Frequency: 1-10Hz. Power: 4x AAA alkaline batteries. Standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-2-10. Software level of concern: Moderate.
Indications for Use
Indicated for symptomatic relief and management of chronic intractable pain, adjunctive treatment of post-surgical or post-traumatic acute pain, and pain control during rehabilitation. Contraindicated in patients with known neurological disorders.
Regulatory Classification
Identification
A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.
Predicate Devices
Related Devices
- K220578 — Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1) · Bozhou Rongjian Medical Appliance Co., Ltd. · May 25, 2022
- K082377 — TENSCARE ITOUCH MODEL(S) EASY AND PLUS · Tenscare, Ltd. · Feb 9, 2009
- K112148 — POWERED MUSCLE STIMULATOR · Valmed, SA · Apr 30, 2012
- K041164 — L-TENS · Fuji Dynamics Limited · May 20, 2004
- K052813 — FD TENS 2030, MODEL DFJ24T · Fuji Dynamics Limited · Jan 25, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features the department's name encircling a symbol. The symbol consists of three stylized human profiles facing right, stacked on top of each other, with flowing lines extending from the bottom profile. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 18, 2017
Xavant Technology (PTY) Ltd Roche Janse van Rensberg Chairman Unit 102 The Tannery Industrial Park 309 Derdepoort Road Silverton, ZA 0184 Gauteng
Re: K161091
Trade/Device Name: STIMPOD NMS460 Nerve Stimulator Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator For Pain Relief Regulatory Class: Class II Product Code: GZJ Dated: December 2, 2016 Received: December 2, 2016
Dear Roche van Rensberg:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
{1}------------------------------------------------
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
| William J. | Digitally signed by William J. Heetderks -A |
|--------------|---------------------------------------------|
| | DN: c=US, o=U.S. Government, ou=HHS, |
| | ou=NIH, ou=People, |
| | 0.9.2342.19200300.100.1.1=0010149848, |
| Heetderks -A | cn=William J. Heetderks -A |
| | Date: 2017.01.18 16:51:40 -05'00' |
for
Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K161091
Device Name STIMPOD NMS460 Nerve Stimulator
#### Indications for Use (Describe)
The STIMPOD NMS460 Nerve Stimulator is a Transcutaneous Electrical Nerve Stimulation (TENS) device used for symptomatic relief and management of chronic intractable pain and/or as an adjunctive treatment of post-surgical pain, post traumatic acute pain problems, as well as an adjunct for pain control due to rehabilitation.
Type of Use (Select one or both, as applicable)
| <span style="font-size:100%;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) |
|-------------------------------------------------------------------------------------|
| <span style="font-size:100%;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
### This 501(k) summary is prepared in accordance with the requirements of 21 CFR 807.92 K161091
### Date this Summary was Prepared [21CFR807.92(a)(1)]
Date Prepared: February 2016
### Submitter's Information [21CFR807.92(a)(1)]
| Company Name: | XAVANT TECHNOLOGY (PTY) LTD |
|-----------------|--------------------------------------|
| Street Address: | Unit 102 The Tannery Industrial Park |
| | 309 Derdepoort Road |
| | Silverton |
| City: | Pretoria |
| State/Province: | Gauteng |
| Country: | South Africa |
| Telephone: | +27(0) 12 743 5959 |
| Facsimile: | +27(0) 86 547 0026 |
| Contact Person: | R. Janse van Rensburg |
| Contact Title: | Chairman |
| Contact Email: | roche@xavant.com |
#### Trade Name, Common Name, Classification [21CFR807.92(a)(2)]
Trade Name: STIMPOD NMS460 Nerve Stimulator Common Name: TENS (Transcutaneous Electronic Nerve Stimulator) device Device Class: Class II Product Code: GZJ (Stimulator, nerve, transcutaneous)
### Identification of Predicate Device(s) [21CFR807.92(a)(3)[
| PREDICATE DEVICES |
|--------------------------------------------------------------------------------------------------------------------------------|
| The STIMPOD NMS460 Nerve Stimulator is similar to the following predicate device as<br>a TENS device under classification GZJ: |
| Acticare (K081835), Bioinduction Ltd |
| The STIMPOD NMS460 Nerve Stimulator mapping probe is similar to the following<br>predicate device<br>under classification BXN: |
| STIMPOD NMS400 (K093591), Xavant Technology |
{4}------------------------------------------------
### Description of the Device [21CFR807.92(a)(4)]
The STIMPOD NMS460 Nerve Stimulator is a hand held low frequency neuromodulation Transcutaneous Electrical Nerve Stimulation (TENS) device, used for symptomatic relief and management of chronic intractable pain and/or as an adjunctive treatment in the management of post-surgical pain, post traumatic acute pain, as well as an adjunct for pain control due to rehabilitation exercises.
The STIMPOD NMS460 Nerve Stimulator offers two types of waveforms for the management of pain. The first is a Monophasic Square Wave, which is typical of normal TENS machines. The second waveform is a Hybrid RF waveform which consists of a Monophasic Square Wave with a superimposed Radio Frequency waveform. This waveform is proprietary and is unique to STIMPOD NMS460 Nerve Stimulator.
| Parameters | STIMPOD NMS460 Nerve<br>Stimulator (Subject device) | Acticare (Predicate device)<br>K081835 |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications for Use | The STIMPOD NMS460<br>Nerve Stimulator is a low<br>frequency neuromodulation<br>Transcutaneous Electrical<br>Nerve Stimulation device,<br>used for symptomatic relief<br>and management of chronic<br>intractable pain and/or as an<br>adjunctive treatment in the<br>management of post-surgical<br>pain, post traumatic acute<br>pain, as well as and adjunct<br>for pain control due to<br>rehabilitation exercises | As a transcutaneous<br>electronic nerve<br>stimulation(tens) device for:<br>the symptomatic relief of<br>chronic intractable pain, and<br>as an adjunctive treatment in<br>the management of post-<br>surgical or post traumatic<br>pain.<br><br>As a neuromuscular<br>electrostimulation (nmes)<br>device for: the relaxation of<br>muscle spasm, prevention of<br>retardation of disuse atrophy,<br>increasing local blood<br>circulation, muscle re-<br>education, immediate post-<br>surgical stimulation of the<br>calf muscles to prevent<br>venous thrombosis and to<br>maintain or increase the<br>range of motion. |
| Number of Output Modes | 1 | 5 (Normal, Powerful, Long<br>Pulse, Burst Mode 1 and 2) |
| Number of Waveforms | 2 (Monophasic, Biphasic<br>with offset) | 3 (Monophasic, Biphasic,<br>Twin Peak) |
| Number of Output<br>Channels | 1 | 1 |
| Method of Channel<br>Isolation | N/A | N/A |
| Current/Voltage Source | Current source | Voltage source |
| Automatic Overload | Yes | N/A |
Indications for Use and Substantial Equivalence [21 CFR807.92(a)(5)]
{5}------------------------------------------------
| Detection | | |
|---------------------------------------|------------------------------------------|------------------------------------|
| Automatic No-Load<br>Detection | Yes | Yes |
| Automatic Shut Off | Yes | |
| User Override Control | Yes | Yes |
| Housing Materials and<br>Construction | ABS Plastic | ABS Plastic |
| Current Range | 0-30mA | 20mA |
| Pulse width options | 0.1ms, 0.2ms | 0.005ms to 0.1ms |
| Maximum stimulation<br>voltage | 220V | 250V |
| Maximum output current | 43.7mA | 127mA |
| Net charge | $6.06\mu C$ | $14.88\mu C$ |
| Maximum Current Density | $93.28\mu A/mm^2$ @500Ohm | $232.62\mu A/mm^2$ @500Ohm |
| Maximum Average Power<br>Density | $71.5\mu W/mm^2$ @500Ohm | $378.575\mu W/mm^2$ @500Ohm |
| Waveform | Monophasic square<br>wave/Hybrid RF wave | Biphasic, Monophasic, Twin<br>Peak |
| Stimulation Frequency | 1Hz, 2Hz, 5Hz, 10Hz +5% | 1Hz to 500kHz |
| Load Impedance | 7kOhm | 12.5kOhm |
| Treatment Timer<br>Maximum | 99 minutes | 180 minutes |
| Device Classification | Class IIa, Type BF | Class IIa, Type BF |
| Power Supply | 4 x AAA alkaline batteries | 4 x AA alkaline batteries |
### Technological Characteristics [21CFR807.92(a)(6)]
The STIMPPOD NMS460 Nerve Stimulator is very similar to the predicate device and has technology characteristics that are substantially equivalent to the predicate device.
The STIMPOD NMS460 and the Acticare predicate device transmit electrical pulses through the skin. The range of amplitudes, pulse widths, frequencies and polarities delivered by the STIMPOD NMS460 Nerve Stimulator is within the ranges delivered by the predicate device.
The STIMPOD NMS460 Nerve Stimulator and the predicate device can be used in clinical environments.
Summary of detailed comparison between the Stimpod NMS460 and Acticare devices for the listed worst-case scenarios:
| Device | Calculation/Result | Mode | Load/s |
|----------------------------------------------|--------------------|------------------------|---------|
| Maximum output Voltage | | | |
| NMS460 | 228V | Monophasic Square Wave | 10 kOhm |
| Acticare | 62.4V | Monophasic Square Wave | 5 kOhm |
| Maximum output Current | | | |
| NMS460 | 43.7mA (Peak) | Hybrid RF Mode | 500 Ohm |
| Acticare | 127mA (Peak) | Monophasic Square Wave | 500 Ohm |
| Maximum Average Current (Over primary phase) | | | |
| NMS460 | 29.85mA | Monophasic Square Wave | 500 Ohm |
{6}------------------------------------------------
| Acticare | 74.44mA | Monophasic Square Wave | 500 Ohm |
|-------------------------------|------------------------------------|------------------------|---------|
| Duration of primary phase | | | |
| NMS460 | 206us | Hybrid RF Mode | 10 kOhm |
| Acticare | 200.4us | Monophasic Square Wave | 5 kOhm |
| Pulse Duration | | | |
| NMS460 | 206us | Hybrid RF Mode | 10 kOhm |
| Acticare | 200.4us | Monophasic Square Wave | 5 kOhm |
| Net Charge | | | |
| NMS460 | 6.06 uC | Hybrid RF Mode | 500 Ohm |
| Acticare | 14.88 uC | Monophasic Square Wave | 500 Ohm |
| Maximum Average Phase Charge | | | |
| NMS460 | 6.06 uC | Hybrid RF Mode | 500 Ohm |
| Acticare | 14.88 uC | Monophasic Square Wave | 500 Ohm |
| Maximum Current Density | | | |
| NMS460 | $93.281 x 10^{-6} \frac{A}{mm^2}$ | Hybrid RF Mode | 500 Ohm |
| Acticare | $232.619 x 10^{-6} \frac{A}{mm^2}$ | Monophasic Square Wave | 500 Ohm |
| Maximum Average Power Density | | | |
| NMS460 | $591.783 x 10^{-6} \frac{W}{mm^2}$ | Hybrid RF Mode | 5 kOhm |
| Acticare | $378.575 x 10^{-6} \frac{W}{mm^2}$ | Monophasic Square Wave | 500 Ohm |
As indicated above the Acticare can deliver up to three times as much peak current and more than twice the average phase current compared to the NMS460. For the selected pulse width of 200us, both units performed within 5% of the pulse width setting. With regards to the net charge and maximum average phase charge and maximum current density, the Acticare again has significantly higher values than the Stimpod NMS460 Nerve Stimulator.
Considering these factors, it is reasonable to conclude that the Stimpod NMS460 Nerve Stimulator is substantially equivalent regarding safety to the Acticare.
Comparison of RF component of Hybrid RF Waveform of Stimpod NMS460 Nerve Stimulator with Burst Modes in the RF range of the Acticare:
| RF Stimulating Options | | |
|-------------------------------|-----------------------------------------------|--------------------------------------|
| | Articare TSE (refer to Appendix B for detail) | Stimpod NMS460 Nerve Stimulator |
| Waveform Options | Biphasic, Monophasic, Twin Peak | Biphasic, with a DC offset, decaying |
| Pulse Width Options | $10\u03bcs$ – 2s | $100\u03bcs$ , $200\u03bcs$ |
| Pulse Repetition Rate Options | 0.25Hz – 2kHz | 1,2,5,10 Hz |
| RF Frequency Options | 5kHz - 500kHz | 160kHz fixed |
As indicated above the RF parameters offered by the Stimpod NMS460 Nerve Stimulator are well within the range of RF parameters offered by the Articare TSE as far as frequency of stimulation, pulse widths, pulse repetition rates and current amplitude are concerned.
{7}------------------------------------------------
Based on the fact that the Stimpod NMS450 Nerve Stimulator is designed as a current source and delivers according to its specification for loads up to 5 kOhm, it is reasonable to conclude that the NMS460 is substantially equivalent to the Acticare regarding effectiveness.
#### Contra-indications
Known neurological disorders.
#### Biocompatibility
Materials used in the manufacture of the STIMPOD NMS460 Nerve Stimulator are safe and pose no threat or danger if they come into contact with human skin. Both the stainless steel (316L) used in the construction of the probe and the ABS plastic used in the manufacture of the enclosure have previously been used in the manufacture of medical and surgical instruments. The materials, referring to the stainless steel and ABS plastic, have also been previously used in FDA approved medical devices (K093591).
The material used and the physical properties of the materials that come into contact with the patient are equivalent with the comparative devices and pose no danger to the patient.
#### Software level of concern
Software level of concern: Moderate
### Non-clinical Testing [21CFR807.92(b)(1)]
Electrical Safety
The STIMPOD NMS460 Nerve Stimulator was tested for patient safety in accordance with the following standards:
IEC 60601-1: 2005, Medical electrical equipment - Part 1: General requirements for basic safety and essential performance.
Test results indicated that the STIMPOD NMS460 Nerve Stimulator complies with the applicable Standards.
Electromagnetic Compatibility
The STIMPOD NMS460 Nerve Stimulator was tested for EMC in accordance with the following standard:
IEC 60601-1-2: 2007, Medical Electrical Equipment, Part 1-2: General Requirements for Safety - Collateral Standard: Electromagnetic Compatibility-Requirements and Tests.
Test results indicated that the STIMPOD NMS460 Nerve Stimulator complies with the applicable Standard.
Safety of Nerve and Muscle Stimulators
The STIMPOD NMS460 Nerve Stimulator was tested for the requirements for safety of nerve and muscle stimulators:
IEC 60601-2-10: 2015. Particular requirements for the basic safety and essential performance of nerve and muscle stimulators.
Test results indicated that the STIMPOD NMS460 Nerve Stimulator complies with the applicable Standard.
{8}------------------------------------------------
## Conclusion [21CFR807.92(b)(3)]
The STIMPOD NMS460 and the Acticare predicate device have the same intended use and similar technical characteristics, performances and applications. The information supplied in the full 510(k) application illustrates that the device does not pose any new question of safety or effectiveness. STIMPOD NMS460 is substantially equivalent to the predicate device.
